Elagolix, an Oral GnRH Antagonist, Versus Subcutaneous Depot Medroxyprogesterone Acetate for the Treatment of Endometriosis: Effects on Bone Mineral Density

This randomized double-blind study, with 24-week treatment and 24-week posttreatment periods, evaluated the effects of elagolix (150 mg every day, 75 mg twice a day) versus subcutaneous depot medroxyprogesterone acetate (DMPA-SC) on bone mineral density (BMD), in women with endometriosis-associated...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Carr, Bruce, Dmowski, W. Paul, O’Brien, Chris, Jiang, Ping, Burke, Joshua, Jimenez, Roland, Garner, Elizabeth, Chwalisz, Kristof
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: SAGE Publications 2014
Gaiak:
Original Articles
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4212335/
https://ncbi.nlm.nih.gov/pubmed/25249568
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1933719114549848
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak